← do dużych inwestorów
SR One Capital Management, LP
inwestor instytucjonalny · portfel $1.04 mld · 15 pozycji · raport na 30.06.2026
Pozycje w akcjach raport za 30.06.2026, złożony 12.08.2026; zmiana — względem 31.03.2026 · 17
| Spółka | Akcje | Wartość | % portfela | Zmiana kwartalna |
|---|---|---|---|---|
| Veradermics, Incorporated US:MANE | 2 401 868 | $295 mln | 28.42% | — |
| Zenas BioPharma, Inc. US:ZBIO | 5 037 854 | $128 mln | 12.31% | — |
| CRISPR Therapeutics AG CUSIP H17182108 | 2 038 763 | $111 mln | 10.70% | — |
| Avalyn Pharma Inc. US:AVLN | 3 308 649 | $109 mln | 10.48% | nowa |
| Design Therapeutics Inc US:DSGN | 6 526 476 | $94.4 mln | 9.09% | — |
| Odyssey Therapeutics, Inc. US:ODTX | 3 794 883 | $71.0 mln | 6.83% | nowa |
| Alumis Inc US:ALMS | 1 959 896 | $55.2 mln | 5.31% | — |
| Oric Pharmaceuticals, Inc. US:ORIC | 4 615 384 | $50.0 mln | 4.81% | +100 455 |
| Mineralys Therapeutics, Inc. US:MLYS | 1 563 966 | $42.2 mln | 4.06% | — |
| ARS Pharmaceuticals, Inc US:SPRY | 4 012 903 | $32.1 mln | 3.09% | — |
| Mobia Medical, Inc. US:MOBI | 1 986 072 | $26.6 mln | 2.56% | nowa |
| Nkarta Inc US:NKTX | 3 333 333 | $9.43 mln | 0.91% | — |
| Oculis Holding AG CUSIP H5870P102 | 641 022 | $8.89 mln | 0.86% | — |
| Ultragenyx US:RARE | 137 753 | $4.60 mln | 0.44% | — |
| enGene Holdings Inc. CUSIP 29286M105 | 747 750 | $1.29 mln | 0.12% | — |
| Arcellx, Inc. CUSIP 03940C100 | 0 (było 2 346 630) | — | — | sprzedana |
| Oruka Therapeutics, Inc. US:ORKA | 0 (było 430 330) | — | — | sprzedana |
W spółkach z naszej bazy 11
| Spółka | Udział | Akcje | Data raportu |
|---|---|---|---|
| Design Therapeutics Inc | 10.43% | 6 526 476 | 2026-06-30 |
| Odyssey Therapeutics, Inc. | 7.89% | 3 794 883 | 2026-06-30 |
| Avalyn Pharma Inc. | 7.46% | 3 308 649 | 2026-06-30 |
| Zenas BioPharma, Inc. | 7.43% | 5 037 854 | 2026-06-30 |
| Mobia Medical, Inc. | 5.97% | 1 986 072 | 2026-06-30 |
| Veradermics, Incorporated | 5.75% | 2 401 868 | 2026-06-30 |
| Nkarta Inc | 4.65% | 3 333 333 | 2026-06-30 |
| ARS Pharmaceuticals, Inc | 4.04% | 4 012 903 | 2026-06-30 |
| CRISPR Therapeutics AG | 2.11% | 2 038 763 | 2026-06-30 |
| Oculis Holding AG | 1.11% | 641 022 | 2026-06-30 |
| ADARx Pharmaceuticals, Inc. | — | — | 2026-09-28 |
reklama
